Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Siga’s Tpoxx Study Enrollment Slows as Monkeypox Cases Wane

Sept. 30, 2022, 7:47 PM

Enrollment in Siga Technologies Inc.’s monkeypox treatment trial is facing a slowdown as a decline in cases makes it more difficult to recruit volunteers.

The National Institutes of Health opened its monkeypox treatment study, known as the STOMP trial, about three weeks ago to evaluate the safety and efficacy of Tpoxx. The Food and Drug Administration approved the antiviral for smallpox in 2018 and the trial will bring crucial answers about how well the drug works in humans for a close cousin of the smallpox virus.

New cases have decelerated week over week, with 25,600 cases identified in ...